P2D BIOSCIENCE

At P2D, our experienced drug development team utilizes “Targeted Phenotypic Screening” and transgenic preclinical models of neurodegenerative diseases to accelerate our drug development process. Our goal is to advance a product candidate through preclinical efficacy testing, GLP-safety studies and early clinical safety and clinical proof-of-concept studies then seek partners to complete the clinical development and commercialization process.